Clinical trials: Withdrawal Syndrome
Cystic Fibrosis, Drug Withdrawal
Qualitative Understanding of Experiences With the SIMPLIFY Trial
This qualitative longitudinal study is designed to elicit and thematically analyze the perspectives of SIMPLIFY subjects about treatment withdrawal research and treatment burden in the context of triple combination CFTR (Cystic…
- Trial name
- QUEST (NCT04320381)
- Testing
- Qualitative Interview
- Where
- 2 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Neonatal Opioid Withdrawal Syndrome
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome
- Trial name
- NOWSHINE (NCT04104646)
- Testing
- CHF6563, Morphine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cannabis Dependence, Tobacco Use
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use
Aims: To characterize the pattern of cannabis and tobacco use and withdrawal symptoms in people who start treatment for cannabis use disorders (exclusive cannabis, concurrent and/or simultaneous with various tobacco products)…
- Conditions
- Cannabis Dependence, Tobacco Use, Withdrawal Syndrome, Substance Abuse
- Trial name
- DuCATA_GAMCaT (NCT05512091)
- Volunteers
- 282 people
- Sponsor
- Cristina Martínez Martínez
Neonatal Opioid Withdrawal Syndrome
Randomized Control Trial of Buprenorphine vs. Morphine for the Treatment of Neonatal Opioid Withdrawal Syndrome (NOWS)
This randomized control trial will compare buprenorphine and morphine, two currently used medications for the treatment of neonatal opioid withdrawal syndrome (NOWS), in newborns to determine which medication will reduce the…
- Trial name
- NCT04455802
- Where
- United States
- Sponsor
- Women and Infants Hospital of Rhode Island
Dexmedetomidine, Midazolam
Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs.
Study will be conducted in Pediatric Intensive Care Unit (PICU) in King Abdullah Specialist Children Hospital (KASCH), National Guard Health Affairs, Riyadh, Saudi Arabia.
- Conditions
- Dexmedetomidine, Midazolam, Withdrawal Symptoms, Failure of Extubation
- Trial name
- PROMISE (NCT05485519)
- Testing
- Dexmedetomidine, Midazolam
- Where
- Saudi Arabia
- Volunteers
- 430 people
- Sponsor
- King Abdullah International Medical Research Center
COVID-19, ARDS
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
The analgesic and sedation requirements in critically ill patients with COVID-19 have yet to be described. There are various factors that are likely affecting the agents being utilized for analgesia and sedation in these patients…
- Conditions
- COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
- Trial name
- NCT05336656
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Wilkes University
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.
- Conditions
- Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal, Neonatal Opioid Withdrawal Syndrome
- Trial name
- NCT04298853
- Testing
- Morphine PRN, Morphine scheduled
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Opiate Withdrawal Syndrome
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
Tramadol abuse is a public health problem in Egypt. There are no approved medications for treatment of withdrawal symptoms or prevention of relapse in patients with tramadol abuse.
- Trial name
- NCT05569031
- Testing
- Venlafaxine, Lofexidine
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Zagazig University
Opioid Withdrawal, Postoperative Pain
Opioid Tapering After Spine Surgery
The effect of a tapering plan combined with telephone counselling to assist patients in opioid tapering after surgery remains unexplored.
- Trial name
- NCT04140955
- Testing
- Tapering plan and telephone counselling
- Where
- Denmark
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Withdrawal Syndrome, Iatrogenic Disease
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
Withdrawal from opioids and sedatives administered for medical purposes (i.e. iatrogenic withdrawal) often goes unrecognized in the critically ill, but its prevalence is high.
- Trial name
- NCT04422808
- Where
- United States
- Volunteers
- 2,437 people
- Sponsor
- Wilkes University
Alcohol Withdrawal Syndrome
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when…
- Trial name
- NCT05438641
- Testing
- BZDP-Sparing Protocol, BZDP-Based Protocol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Drug Withdrawal Symptoms, Critical Care
Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment
The study is a prospective interventional study with three main aims: 1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2.
- Conditions
- Drug Withdrawal Symptoms, Critical Care, Child
- Trial name
- ASWISPIC (NCT02952846)
- Testing
- Algorithm for tapering og analgosedation
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital
Alcohol Withdrawal Syndrome
Gabapentin for Alcohol Withdrawal Syndrome
The current "gold-standard" for the management of alcohol withdrawal syndrome (AWS) is symptom-triggered administration of benzodiazepines.
- Trial name
- NCT03012815
- Testing
- Gabapentin, Benzodiazepines, Divalproex Sodium
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Mayo Clinic
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.
- Trial name
- NCT01863186
- Testing
- Lofexidine HCl, Open Label Lofexidine HCL
- Where
- 18 sites in United States
- Volunteers
- 603 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Smoking Cessation, Withdrawal Symptoms
The Effect of Honey on Lessening the Withdrawal Symptoms
This project investigates the effect of honey on lessening the withdrawal symptoms according to the body constitution.
- Trial name
- NCT05264428
- Testing
- Honey, Water
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Alcohol Withdrawal Syndrome
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS.
- Trial name
- MAGMA (NCT03033823)
- Testing
- Magnesium
- Where
- 11 sites in France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Withdrawal Syndrome
Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)
This interventional study evaluates the efficacy of dexmedetomidine during weaning from analgesic and sedative drugs in reducing the occurrence of the withdrawal syndrome in PICU.
- Trial name
- TIP-15-01 (NCT03645603)
- Testing
- Dexmedetomidine
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Alcohol Use Disorder, Addiction
Portrayal of Hospital Alcohol Detoxification in France
Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients…
- Conditions
- Alcohol Use Disorder, Addiction, Alcohol Withdrawal Syndrome
- Trial name
- Alcostop (NCT04973202)
- Testing
- Stay for alcohol detoxification
- Where
- France
- Volunteers
- 50,000 people
- Sponsor
- University Hospital, Montpellier
Substance Use Disorders, Opiate Dependence
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse…
- Conditions
- Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder
- Trial name
- NCT03971097
- Testing
- Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Pittsburgh